Stability Studies in Pharmaceuticals: Guidelines and Recent Advances

Authors :- Suraj Sanjay Shelar [1], Priti Sanjay Pagar[2], Mahesh Kailas Wagh[3]

Professor's:- Guide – D. S. Pachpute , Principal – M.B.Nikam

Designation:- S.V.S Institute Of Pharmacy Mungase, Malegaon, Nashik

Abstract

Regulatory agencies like the ICH, FDA, and WHO have established comprehensive guidelines to standardise stability testing globally. Various regulatory guidelines recommend establishing a stability profile of pharmaceuticals at the time of drug development. Stability analysis is used to determine the expiration date, retesting period, and storage conditions of active drugs or products. Regulatory agencies like the FDA, WHO, and ICH have established comprehensive guidelines to standardise stability testing globally. This review examines the key principles, regulatory requirements, and recent advancements in stability studies, including novel analytical techniques, predictive modelling, and the impact of emerging technologies on stability assessment. Mostly, ICH stability guidelines are followed in practice. This guideline recommends to validate stability indicating method using forced degradation samples that contains all possible degradation impurities. ICH guidelines provide general recommendations for inclusion of stability indicating parameters in a stability testing protocol. However, those guidelines do not provide specific requirements and experimental methodology to be followed for stability studies. Due to this gap, often confusion arises in the scientific community in designing stability testing protocol. Therefore, significant variations are observed in reported literature in selection of stability indicating parameters. Procedural dissimilarity amongst reported stability studies is also evident. This review discusses the regulatory guidelines and procedures to follow in performing stability testing of pharmaceuticals. Scope of this review also includes recommendations on practical approaches for designing stability testing protocol to fulfill current regulatory requirements for drug substances and their formulations.

Introduction

Pharmaceutical development relies heavily on stability studies to guarantee the quality, safety, and effectiveness of drug products over the course of their shelf life. A systematic method for evaluating the stability of pharmaceutical products under varied environmental conditions is offered by regulatory guidelines set by organisations like the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), and the International Council for Harmonisation (ICH). In order to prevent product deterioration and guarantee patient safety, these investigations assist in determining the proper storage conditions and expiration dates.

To estimate the shelf life of drug substances and products, traditional stability testing techniques include long-term, accelerated, and stress testing have been widely used. However, the effectiveness and precision of stability predictions have been greatly increased by recent developments in analytical methods, computational modelling, and real-time stability monitoring. Predictive stability modelling, Quality by Design (QbD), and sophisticated spectroscopic techniques are examples of emerging methodologies that have improved risk assessment and deepened our understanding of degradation processes.

Pharmaceutical stability studies evaluate the long-term effects of environmental variables such as temperature, humidity, and light on a drug's quality. By defining shelf life and storage conditions, these studies contribute to the safety and effectiveness of products. The foundation for international regulatory compliance in stability testing is provided by the International Council for Harmonisation (ICH) rules, specifically Q1A(R2).

Keywords

Quality, safety, efficiency, risk assessment ,ICH guidelines, Qbd, FDA

Factors affecting drug stability [17-19]

1 Temperature

The stability of a drug substance is affected by changes in temperature; When the temperature is increased, it causes an increase in the Hydrolysis rate of drugs.

2 Moisture

Some physical and chemical dosage changes when the water-soluble Solid dose is absorbed into any moisture surface and therefore loses Its properties.

3 pH

The deterioration rate of hydrolyzed solution drugs is influenced by pH And reduces the effective drugs that are formulated using buffers at the pH of optimum stability.

4 Excipients

Starch and povidone excipients have greater water content and affect Stability by enhancing the formulations of water content. Furthermore, there are chemical interactions between excipients and drugs that lead To a reduction of instability.

5 Oxygen

Oxygen presence facilitates oxidation in some products. Products with A higher decomposition rate are stabilized when exposed to oxygen By substituting carbon dioxide and nitrogen for oxygen in the storage Container.

6 Light

When exposed to light, the rate of decomposition increases. Certain Drugs are photosensitive and their stability can be measured when Exposed to light or stored in the dark by comparing their stability. Photosensitive medicines must be packed in a glass amber bottle and Held in a dark place.

Regulatory Guidelines for Stability Testing

ICH Guidelines: ICH Q1A(R2) provides general stability requirements, while other guidelines (Q1B-Q1E) address specific aspects like photostability and bracketing designs.

US FDA: Aligns with ICH standards but includes additional guidance for accelerated stability studies.

WHO: Focuses on harmonized global stability requirements, particularly for medicines intended for developing regions.

European Medicines Agency (EMA): Emphasizes climatic zone-based stability protocols.

Recent Advances and Trends

- **QbD (Quality by Design):** Integrating QbD in stability testing enhances predictability and control over product quality.
- **Stability Modeling and Software:** Tools like ASAPprime® allow for predictive modeling, reducing the need for prolonged testing.
- **Green Stability Testing:** Efforts to minimize environmental impact and energy consumption in testing protocols.
- **Nanotechnology and Biologics:** Special considerations for stability testing of complex molecules like monoclonal antibodies and nanoparticles.

Advances in Stability Testing:-

Analytical Techniques

- ❖ Chromatographic Methods: High-performance liquid chromatography (HPLC) and ultra-performance liquid chromatography (UPLC) enhance stability assessments.
- ❖ Spectroscopic Approaches: Fourier-transform infrared (FTIR) and nuclear magnetic resonance (NMR) spectroscopy provide detailed molecular stability insights.
- ❖ Mass Spectrometry (MS): Aids in detecting trace degradation products with high precision.

Predictive Modeling & AI Integration

- ❖ Computational Modeling: Predicts stability profiles using kinetic modeling and artificial intelligence (AI).machine Learning Algorithms: Optimize stability study designs by analyzing vast datasets.
- ❖ In-silico Simulation Tools: Offer early-stage stability predictions, reducing experimental workload.

Emerging Technologies

- ❖ Nanotechnology: Enhances drug stability via nanoformulations.
- ❖ 3D Printing: Provides personalized drug formulations with tailored stability profiles.
- ❖ Smart Packaging: Incorporates indicators and sensors to monitor real-time stability conditions.

Future Perspectives

- ❖ The integration of AI, nanotechnology, and real-time monitoring tools is expected to revolutionize stability studies. Regulatory agencies are adapting guidelines to accommodate novel formulations and emerging analytical techniques. Further research in predictive stability modeling could enhance pharmaceutical development efficiency.

Standing of stability testing in drug development cycle

Stability study can be considered as an integral component of drug development activity. It Describes essential parameters that dictate expiry date of drug products. Physical and Chemical stability of drugs at preclinical formulation stages, during drug development and Packaging development process, are the critical factors to be monitored (Alsante et al., 2014). Insufficient physicochemical stability of drug results in their compromised purity, potency as Well as safety. Safety and efficacy of pharmaceuticals are confirmed at the time of drug Development process through preclinical and clinical studies. Drug instability may result in Lowering the

amount of actual administered dose to the patient. Again, instability may Generate toxic degradation products (Bajaj et al., 2012).

An unstable product may lead to an uncontrolled process that requires a thorough investigation of the product's failure; in extreme cases, the product may need to be taken off the market. Thus, it is essential to conduct stability testing beforehand in order to determine the recommended storage conditions, frequency of retesting, shelf life, and expiration date of the product. Additionally, stability data can suggest that the final formulation be produced and stored under specific environmental conditions, as well as that the product be packaged appropriately. During the drug development process, the reactivity of the drug substance to various factors should be investigated (Thakor et al., 2016). According to stability data produced during the medication development phase, storage conditions must be

Important of stability testing

1 .Ensures Drug Safety and Efficacy

- Stability testing helps determine how long a drug maintains its intended effectiveness and remains safe for use.
- It prevents the distribution of degraded or harmful products to consumers.

2.Determines Shelf Life and Expiry Date

- The data from stability testing help manufacturers establish the product's shelf life and storage conditions.
- It ensures that drugs retain their potency until the expiration date.

3. Compliance with Regulatory Requirements

- Regulatory agencies like the FDA (U.S.), EMA (Europe), and ICH (International Council for Harmonisation) require stability data before approving a drug for market distribution.Non-compliance can lead to product recalls, fines, or rejections.

4. Identifies Potential Degradation Products

- Over time, drugs may degrade into harmful by-products.Stability testing identifies these degradants and ensures they remain within acceptable limits.

5. Guides Storage and Packaging Decisions

- It helps determine the appropriate storage conditions (e.g., refrigeration, room temperature).Assists in selecting packaging materials that protect the drug from environmental factors.

6.Supports Product Development and Formulation

- Stability studies guide pharmaceutical scientists in optimizing formulations to enhance drug stability.
- Ensures product consistency across different batches.

7.Cost Efficiency and Waste Reduction

- By predicting product stability, manufacturers can optimize production and reduce losses due to expired or degraded products.

Type of stability of drug substance

1.Chemical Stability

- Ensures that the active pharmaceutical ingredient (API) maintains its chemical integrity and potency.Prevents degradation due to hydrolysis, oxidation, photolysis, or other chemical reactions.

2.Physical Stability

- Ensures that the drug product retains its original physical properties, such as appearance, texture, dissolution, and suspendability.Examples of instability: changes in color, precipitation in solutions, phase separation in emulsions, or hardness variation in tablets.

3. Microbiological Stability

- Ensures that the drug remains free from microbial contamination throughout its shelf life.Important for sterile formulations (e.g., injectables, eye drops) and non-sterile formulations (e.g., oral suspensions, creams).Requires the use of preservatives to prevent microbial growth.

4. Therapeutic Stability

- Ensures that the drug maintains its intended therapeutic effect over time.Even if a drug remains chemically intact, degradation products or formulation changes can alter its effectiveness.

5. Toxicological Stability

- Ensures that no toxic degradation products are formed over time.Some degradation products may cause adverse effects, making stability testing essential.

6. Photostability

- Ensures that exposure to light (especially UV) does not cause degradation.Some drugs, such as vitamins and antibiotics, are highly light-sensitive and require protective packaging.

7. Mechanical Stability

- Relevant for solid dosage forms like tablets, capsules, and powders.Ensures that physical stress during transportation, handling, and storage does not lead to breakage, caking, or powdering.

STABILITY TESTING METHOD

For drug ingredients and products, stability tests are a standard procedure performed in the different stages of product development. Accelerated stability tests are used in the early stages to gauge the kind of deteriorated products discovered after extended storage. The primary goals of the pharmaceutical stability test are to make sure that goods are fit for human consumption up until the last pharmaceutical unit is utilised and that they stay on the market for as long as their fitness or quality is acceptable.

Stability testing procedures are divided into four groups.

1. Real-time stability testing
2. Accelerated stability testing
3. Retained sample stability testing
4. Cyclic temperature stress testing

1.Real-time stability testing

It is carried out in order to permit significant product deterioration throughout the course of the trial term under storage conditions. The test period depends on product stability, which must be long enough to demonstrate unequivocally that no discernible degradations take place and that degradation must be isolated from interassay variability. By collecting data at the right frequency throughout the test, trend analysis can distinguish instability from daily ambiguity. The stability of reference materials includes the constancy of instrument quality and reagent stability for use in stability studies.

2.Accelerated Stability Testing in Pharmaceuticals

Definition:

- Accelerated stability testing evaluates a drug's stability by exposing it to elevated stress conditions (higher temperature and humidity) to predict its shelf life in a shorter period.

Purpose:

- Provides early stability data for formulation developmentPredicts long-term stability trends.
- Supports shelf-life determination before real-time data is available conditions.

(ICH Q1A(R2) Guidelines):

- Temperature: 40°C ± 2°C
- Humidity: 75% RH ± 5% RH
- Duration: 6 months

Key Tests Conducted:

- Physical (appearance, dissolution, moisture content)
- Chemical (assay, degradation products, pH) Microbiological (sterility, microbial limits)
- Limitations:May not always predict long-term stability accuratelySome degradation pathways may differ from real-time conditi

3. Retained Sample Stability Testing in Pharmaceuticals

Definition:

- Retained sample stability testing involves storing and periodically testing reserve (retained) samples of drug products or raw materials to ensure they remain within specifications throughout their shelf life.

Purpose:

- Confirms product quality over timeSupports investigations in case of complaints or recallsEnsures compliance with regulatory requirements

Storage Conditions:

- Stored under labeled conditions (e.g., room temperature, refrigeration)Typically kept for at least one year after expiration or as per regulations

Key Tests Conducted:

- Physical: Appearance, color, dissolution
- Chemical: Assay, degradation products
- Microbiological: Sterility, microbial limits
- Regulatory Guidelines:ICH Q1A(R2), WHO, FDA, and other regional regulations

4.Cyclic temperature stress testing

Testing for cyclic stress In the development or troubleshooting of pharmaceutical scientists for stability testing, temperature is a highly helpful component, but not for normal product testing [3]. Based on product knowledge, cyclic temperature stress tests are made to simulate potential storage circumstances in the marketplace. Since the earth's diurnal cycle lasts for twenty-four hours, the period of cycle that is typically taken into consideration is twenty-four hours, which is probably what the marketed drugs go through while they are being stored. Minimum and maximum temperatures are advised for cyclic stress testing; these must be selected according to the product and should take into account the product's unique physical and chemical degradation characteristics as well as recommended storage temperatures. Additionally, it implies that the test typically consists of 20 cycles.

ICH Guidelines for Stability Studies

The ICH Q1A(R2) – Stability Testing of New Drug Substances and Products provides the primary framework for stability studies.

Tablet:- ICH Stability Guidelines

Guideline	Description
Q1A	Stability testing of new drug substances and products
Q1B	Stability testing: Photostability testing of new drug substances and products
Q1C	Stability testing for New Dosage Forms.
Q1D	Bracketing and matrixing Designs for Stability testing of new drug substances and products.
Q1E	Evaluation of stability data
Q1F	Stability data package for Registration Applications in Climatic Zones III & IV
Q1/Q5C EWG	Targeted revisions of the ICH Stability Guideline Series

A. Types of Stability Studies

1)Long-term Stability Study:- Conducted at standard storage conditions to establish shelf life.

Conditions (for general climate zones):

25°C ± 2°C / 60% RH ± 5% RH (Zone I & II – Temperate climate

30°C ± 2°C / 65% RH ± 5% RH (Zone III – Hot and dry climate)

30°C ± 2°C / 75% RH ± 5% RH (Zone Iva – Hot and humid climate)

30°C ± 2°C / 75% RH ± 5% RH (Zone IVb – Very hot and humid climate)

Duration: At least 12 months or more, depending on the product.

2)Accelerated Stability Study:-Conducted to predict product degradation under harsh conditions.

- Conditions: 40°C ± 2°C / 75% RH ± 5% RH
- Duration: 6 months minimum
- Used to extrapolate the shelf life and determine recommended storage conditions.

3)Intermediate Stability Study:- Required when long-term storage is at 25°C/60% RH but significant degradation occurs in accelerated conditions.

- Conditions: 30°C ± 2°C / 65% RH ± 5% RH
- Duration: 6 months

4)Photostability Study (ICH Q1B) :-Conducted to evaluate drug product sensitivity to light exposure.

- Conditions: Exposure to light equivalent to 1.2 million lux hours and 200-watt hours/m² UV-A light.

5)Forced Degradation Study (ICH Q1A(R2)):- Not a regulatory requirement but helps in understanding the degradation pathways.

- Conditions:
- Acid/base hydrolysis
- Oxidation
- Thermal stress
- Photolysis

1.Stability Study Testing Parameters

The following tests are required for stability studies:Physical Tests: Appearance, color, odor, moisture content, hardness, and disintegration time.Chemical Tests: Assay (potency), degradation products, related substances, and pH.Microbiological Tests: Sterility (for sterile products), microbial limits, and preservative efficacy.Dissolution Testing: Ensures proper drug release profile.

2. WHO Stability Guidelines

The WHO stability testing guidelines are aligned with ICH but also provide additional recommendations for developing countries. They classify climate zones into four categories, similar to ICH guidelines, and emphasize testing for different regions.
WHO requires bracketing and matrixing approaches to optimize testing while reducing the number of samples needed for large batches.

3. FDA Stability Study Guidelines

Follow ICH Q1A(R2) standards.
Additional container-closure system stability requirements to ensure packaging does not impact the drug product.
Requirements for biological products (such as vaccines) include specific refrigerated and frozen storage conditions.

4.Stability Study Requirements for Different Dosage Forms

Dosage Form Special Stability Considerations Tablets & Capsules Moisture and light sensitivity, dissolution testing Injectables Sterility, particulate matter, pH, and color stability Biologics/Vaccines Cold chain stability (2–8°C, -20°C, -80°C) Ophthalmic Products Preservative efficacy and sterility Suspensions & Solutions Sedimentation, pH, microbial limits Topicals & Creams Phase separation, viscosity, microbial growth

5.Stability Study Documentation

For regulatory submissions, the following documentation is required:Stability Protocol: Defines the study design, testing parameters, and methods.Stability Summary Report: Includes results, statistical analysis, and shelf-life prediction.Certificate of Analysis (CoA): Provided for each batch tested.Regulatory Submission Format: Data must be presented in CTD (Common Technical Document) format for submission to ICH countries.

6.Shelf-Life Estimation

Shelf life is determined using statistical modeling (Arrhenius equation) based on degradation kinetics observed in stability studies. Extrapolation is only allowed when significant supporting data is available.

7.Container Closure System

The stability studies should be conducted on the Active substance packaged in a containerclosure System that is the same as or simulates the Packaging proposed for storage anddistribution.

8.Specification

Stability studies should include testing of those Attributes of the active substance that aresusceptible To change during storage and are likely to influence Quality, safety, and/or Efficacy.The testing should Cover, as appropriate, the physical, chemical, Biological, andmicrobiological attributes. Validated

Stability-indicating analytical procedures should Beapplied. Whether and to what extent replication Should be performed will depend on the resultsfrom Validation studies.

9.Testing Frequency

For long term studies, frequency of testing should Be sufficient to establish the stability profileof the Active substance. For active substances with a Proposed re-test period of at least 12months, the Frequency of testing at the long term storage Condition should normally be everythree months Over the first year, every six months over the Second year, and annually thereafterthrough theProposed re-test period.

Challenges and Future Directions

- Testing for personalized medicines and biologics remains complex.
- Need for harmonization of global regulatory requirements.
- Integration of AI/ML in predictive stability modeling.
- Advancements in container-closure system evaluations.

Discussion

For pharmaceutical goods to remain effective, safe, and of high quality over the course of their shelf life, stability studies are essential. Globally, standardised testing methods are provided by regulatory frameworks such as ICH guidelines (Q1A–Q1F), which cover factors like temperature, humidity, and light exposure. Recent developments in analytical technologies, such as LC-MS and HPLC, have improved the reliability of stability-indicating techniques and improved the detection of degradation products.

Conclusion

Pharmaceutical stability studies guarantee the safety, effectiveness, and quality of drugs over the course of their shelf life. Standardised procedures for stability testing that include climatic zones and degradation routes are provided by regulatory recommendations like ICH Q1A(R2). AI-driven predictive modelling is one recent discovery that speeds up medication development and improves stability predictions. Stability evaluation is improved by real-time monitoring with IoT sensors and smart packaging. NMR and mass spectrometry are examples of sophisticated analytical methods that enhance impurity profiling. To guarantee strong formulations, the Quality by Design (QbD) methodology incorporates risk-based evaluations. Testing periods are shortened by emerging methods like accelerated predictive stability (APS). Stability studies are streamlined by automation and continuous manufacturing. Guidelines that are harmonised globally improve market access and regulatory

compliance. Together, these developments enhance the assessment of medication stability, guaranteeing the long-term safety and quality of pharmaceuticals.

Pharmaceutical businesses can now optimise product stability, expedite regulatory approval, and provide patients around the world with high-quality medications thanks to advancements in stability testing procedures, which are revolutionising pharmaceutical development and manufacturing. In order to solve present issues and foresee future requirements in stability testing, stakeholders can embrace innovation and make use of state-of-the-art technologies.

Reference

1. Stability testing of new drug substances and products—Q1A (R2).(ICH), International Conference on Harmonization. Originallypublished 1994; revised 2003.

2. Stability testing: photostability testing of new drug substances and products—Q1B. (ICH), InternationalConference onHarmonization, 1996.

3. Stability testing for new dosage forms—Q1C. (ICH), International Conference on Harmonization.1996.

4. Bracketing and matrixing designs for stability testing of new drug substances and products—Q1D. (ICH), International Conference on Harmonization. 2002.

5. Evaluation for stability data—Q1E. (ICH), International Conferenceon Harmonization. 2003.

6. Quality of biotechnological products: stability testing of biotechnological/biological products—Q5C. (ICH), International Conferenceon Harmonization. 1995.

7.Technical Report Series, No. 953: Annex 2 Stability testing of active pharmaceutical ingredients and finished pharmaceuticalproducts. WHO. 2009

8.Technical Report no. 46: Last mile: Guidance for good distribution practices For pharmaceutical products to the end User. PDA. 2009.

9.Temperature controlled pharmaceutical Distribution maintaining the quality of Temperature sensitive products in theSupply chain. Representative, FDA. Hotel Fira Palace, Barcelona: IBC Informa life Sciences. 2006.

10.Bhutani H, Mariappan TT and Singh S. Behavior of Uptake of Moisture by Drugs And Excipients under Accelerated Conditions of Temperature and Humidity In the Absence and the Presence of light. Part 2. Packaged and Unpackaged antiTuberculosis drug products. PharTechnol. 2003;27:44-5

11.Bott RF. Oliveira WP. Storage conditions For stability testing of pharmaceuticals in Hot and humid regions. Drug Dev and Indus Pharm. 2007;33:393-401.

12.. Temperature Controlled Pharmaceutical Distribution Conference. Representative, FDA. Amsterdam: IBC Informa life Sciences, 2007.

13.. Seevers RH, Bishara RH, Harber PJ andLucas TI. Designing stability studies for Time/temperature exposure AmericanPharmaceuticalOutsourcing.2005;6(5):18, 20, 21, 23, 55

14. Lucas TI, Bishara RH, Seevers RH. Stability program for the distribution of Drug products.PharmaceuticalTechnology. 2004;1:68-73.

15.. Ammann Claude. A mathematica lApproach to assessing temperatureExcursions in temperature-controlled Chains. European Journal of Parenteral and Pharmaceutical Sciences. 2008;13(2):57–9.

16.Handbook of stability testing in Pharmaceutical development regulations, Methodologies, and best practices. HuynhBa, Kim (Ed.). s.l.: Springer, 2009.

17. Anderson G and Scott M. Determination Of product shelf life and activation energyFor five drugs of abuse. Clin Chem. 1991;37:398-402

18.Bakshi M, Singh S. Development of validated stability-indicating assay Methods-critical review. J Pharm Biomed Anal 2002;28:1011-40.

19. Marin A, Barbas C. LC-MS for the degradation profiling of cough-cold Products under forced conditions. J Pharm Biomed Anal 2004;35:1035-45.

20. Singh S, Junwal M, Modhe G, Tiwari H, Kurmi M. Forced degradation Studies to assess the stability of drugs and products. Trends Analyt Chem 2013;49:71-88.

21. Haystead JS. Stability testing. Pharm Technol 2004;28:130.

22. Colgan ST, Timpano RJ, Roberts M. Opportunities for lean stability Strategies. J Pharm Sci Innov 2014;9:259-71.

23. Singh R, Rehman ZU. Current trends in forced degradation study for Pharmaceutical product development. J Pharm Educ Res 2012;3:54-63.

24. Andreson G, Scott M. Determination of product shelf life and activation For five drugs of abuse. Clin Chem 1991;37:398-402.

25. Chakole RD, Charde MS, Kumar J, Welankiwar AS. Development of Forced degradation studies of drugs. Int J Adv Pharm 2013;2:34-9.

26. Hotha KK, Reddy SP, Raju VK, Ravindranath LK. Overview of Regulatory guidance and literature for the drug products and drug Substances. Int Res J Pharm 2013;4:78-85.

27. Kaur M, Kaur G, Kaur H, Sharma S. Overview on stability studies. Int J Pharm Chem Biol Sci 2013;3:1231-41.

28. World Health Organization. Stability Studies in a Global Environment. Geneva: World Health Organization; 2004.

29. Veszelszki A. Stability testing of active pharmaceutical ingredients and Finished pharmaceutical products. WHO Tech Rep Ser 2018;10:309-52.

30. Singh S. Stability testing during product development. In: Jain NK. Pharmaceutical Product Development. India: CBS Publisher; 2000. P. 272-93.

31. Pokharana M, Vaishnav R, Goyal A, Shrivastava A. Stability testing Guidelines of pharmaceutical products. J Drug Deliv Ther 2018;8:169-75.

32. International Conference on Harmonization. Guideline on Stability Testing of New Drug Substances and Products, Q1A (R2); 2003.

33. International Conference on Harmonization. Stability Testing: Photostability Testing of New Drug Substances and Products, Q1B;

1996. Available from: https://www.database.ich.org/sites/default/files/ Q1b20guideline.pdf. [Last accessed on 2020 Mar 20].

34. International Conference on Harmonization. Stability Testing for New Dosage Forms, Q1C;1996 Available from: https://www.database.ich.org/ Sites/default/files/Q1C20Guideline.pdf. [Last accessed on 2020 Mar 20].

35. International Conference on Harmonization. Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products, Q1D; 2002. Available from: https://www.database.ich.org/sites/default/ Files/q1d20guideline.pdf. [Last accessed on 2020 Mar 20].

36. Munden RP. ICH Q1D: ICH Quality Guideline; 2017. P. 73-87.

37. International Conference on Harmonization. Evaluation for Stability Data, Q1E; 2003. Available from: https://www.database.ich.org/sites/ Default/files/q1e20guideline.pdf. [Last accessed on 2020 Mar 20].

38. International Conference on Harmonization. Stability Data Package For Registration Application in Climatic Zone III and IV, Q1F; 2018. Available from: https://www.database.ich.org/sites/default/files/q1f_Stability_guideline_who_2018.pdf. [Last accessed on 2020 Mar 20].

39. International Conference on Harmonization. Stability Testing Biotechnological/Biological Products, Q5C; 1995. Available from:https://www.database.ich.org/sites/default/files/q5c20guideline.pdf. [Last accessed on 2020 Mar 20].

40. Hasija, M, Aboutorabian, S, Rahman, N Ausar, SF. Practical Approaches to forced degradation studies of vaccines. Methods Mol Biol 2016;1403:853-66.

41. International Conference on Harmonization. GMP Guide for Active Ingredients, Q7; 2000. Available from: https://www.database.ich.org/Sites/default/files/q720guideline.pdf. [Last accessed on 2020 Mar 20].

42. European Medicines Agency. Guideline on Stability Testing: Stability Testing of Existing Active Substances and Related Finished Products, CPMP/QWP/122/02. Amsterdam: European Medicines Agency; 2003.

Available from: https://www.ema.europa.eu/en/documents/scientificguideline/guideline-stability-testing-stability-testing-existing-activesubstances-related-finished-products_en.pdf. [Last accessed on 2020 Apr 02].

43. Bott RF, Oliveira WP. Storage conditions for stability testing of Pharmaceuticals in hot and humid regions. Drug Dev Ind Pharm 2007;33:393-401.

44. Grimm W. Extension of the international conference on harmonization Tripartite guideline for stability testing of new drug substances and Products to countries of climatic zones III and IV. Drug Dev Ind Pharm 1998;24:313-25.

45. World Health Organization. Stability Testing of Active Pharmaceutical Ingredients and Finished Pharmaceutical Products. WHO Technical Report Series; 2009. Available from: https://www.extranet.who.int/Prequal/sites/default/files/documents/trs1010_annex10.pdf. [Last Accessed on 2020 Apr 02].

46. Ali J, Khar RK, Ahuja A. Dosage form and Design. 3rd ed. Delhi: Birla Publications Pvt. Ltd.; 2008. P. 100-23.

47. Baertschi SW. Pharmaceutical Stress Testing. Predicting Drug Degradation. India: CRC Press; 2005